{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:25:16Z","timestamp":1772756716989,"version":"3.50.1"},"reference-count":108,"publisher":"American Diabetes Association","issue":"Supplement_2","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,8,1]]},"abstract":"<jats:p>Sodium\u2013glucose cotransporter 2 inhibitors (SGLT2i) are the most recent addition to the therapeutic options available for the treatment of type 2 diabetes and became available after the introduction of incretin-based therapies, dipeptidyl peptidase 4 inhibitors and glucagon-like peptide 1 receptor agonists (GLP-1 RAs). These agents have potential advantages with regard to their weight loss\u2013promoting effect, low risk of hypoglycemia, reduction in blood pressure, and reduction in cardiovascular events in high-risk patients (with empagliflozin). Apart from these clinically important outcomes, they may also correct core defects present in type 2 diabetes (i.e., improvement in \u03b2-cell function and insulin sensitivity). They do, however, have some adverse effects, notably, nausea with GLP-1 RAs and genital tract infections and potential for volume depletion with SGLT2i. Whether incretin-based therapies are associated with an increased risk of pancreatitis is unclear. Most recently, diabetic ketoacidosis has been reported with SGLT2i. Therefore, a key clinical question in relation to guidelines is whether these clinical advantages, in the context of the adverse effect profile, outweigh the additional cost compared with older, more established therapies. This article reviews the therapeutic rationale for the use of these newer drugs for diabetes treatment, considers their place in current guidelines, and discusses how this may change as new data emerge about their long-term efficacy and safety from ongoing outcome trials.<\/jats:p>","DOI":"10.2337\/dcs15-3005","type":"journal-article","created":{"date-parts":[[2016,7,20]],"date-time":"2016-07-20T09:52:32Z","timestamp":1469008352000},"page":"S154-S164","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":35,"title":["Positioning SGLT2 Inhibitors\/Incretin-Based Therapies in the Treatment Algorithm"],"prefix":"10.2337","volume":"39","author":[{"given":"John P.H.","family":"Wilding","sequence":"first","affiliation":[{"name":"Obesity and Endocrinology Clinical Research, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surya Panicker","family":"Rajeev","sequence":"additional","affiliation":[{"name":"Obesity and Endocrinology Clinical Research, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph A.","family":"DeFronzo","sequence":"additional","affiliation":[{"name":"Diabetes Division, The University of Texas Health Science Center at San Antonio, San Antonio, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","published-online":{"date-parts":[[2016,7,16]]},"reference":[{"key":"2022031221285805700_B1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0140-6736(64)90011-X","article-title":"New interpretation of oral glucose tolerance","volume":"2","author":"McIntyre","year":"1964","journal-title":"Lancet"},{"key":"2022031221285805700_B2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2337\/diab.43.4.535","article-title":"Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans","volume":"43","author":"Orskov","year":"1994","journal-title":"Diabetes"},{"key":"2022031221285805700_B3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s00125-010-1896-4","article-title":"Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down","volume":"54","author":"Nauck","year":"2011","journal-title":"Diabetologia"},{"key":"2022031221285805700_B4","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00125-002-0878-6","article-title":"Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients","volume":"45","author":"Vilsb\u00f8ll","year":"2002","journal-title":"Diabetologia"},{"key":"2022031221285805700_B5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00125-008-1195-5","article-title":"Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes","volume":"52","author":"H\u00f8jberg","year":"2009","journal-title":"Diabetologia"},{"key":"2022031221285805700_B6","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1210\/jcem.87.3.8355","article-title":"Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers","volume":"87","author":"Nauck","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031221285805700_B7","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.2337\/diabetes.53.9.2397","article-title":"Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia","volume":"53","author":"Degn","year":"2004","journal-title":"Diabetes"},{"key":"2022031221285805700_B8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/379069a0","article-title":"A role for glucagon-like peptide-1 in the central regulation of feeding","volume":"379","author":"Turton","year":"1996","journal-title":"Nature"},{"key":"2022031221285805700_B9","first-page":"R848","article-title":"Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats","volume":"271","author":"Tang-Christensen","year":"1996","journal-title":"Am J Physiol"},{"key":"2022031221285805700_B10","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1463-1326.2009.01158.x","article-title":"Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue","volume":"11","author":"Jendle","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"2022031221285805700_B11","first-page":"327","article-title":"Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients","volume":"81","author":"Willms","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031221285805700_B12","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(02)07952-7","article-title":"Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study","volume":"359","author":"Zander","year":"2002","journal-title":"Lancet"},{"key":"2022031221285805700_B13","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/dmrr.1114","article-title":"Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus","volume":"26","author":"Scheen","year":"2010","journal-title":"Diabetes Metab Res Rev"},{"key":"2022031221285805700_B14","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S2213-8587(14)70251-7","article-title":"Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study","volume":"3","author":"Inagaki","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031221285805700_B15","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.298.2.194","article-title":"Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis","volume":"298","author":"Amori","year":"2007","journal-title":"JAMA"},{"key":"2022031221285805700_B16","doi-asserted-by":"crossref","first-page":"e103798","DOI":"10.1371\/journal.pone.0103798","article-title":"Comparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studies","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"key":"2022031221285805700_B17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1463-1326.2010.01306.x","article-title":"Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review","volume":"13","author":"Deacon","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"2022031221285805700_B18","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1007\/s00125-007-0633-0","article-title":"Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes","volume":"50","author":"Fonseca","year":"2007","journal-title":"Diabetologia"},{"key":"2022031221285805700_B19","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/j.1463-1326.2009.01124.x","article-title":"Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia","volume":"11","author":"Rosenstock","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"2022031221285805700_B20","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMp1314078","article-title":"Pancreatic safety of incretin-based drugs--FDA and EMA assessment","volume":"370","author":"Egan","year":"2014","journal-title":"N Engl J Med"},{"key":"2022031221285805700_B21","doi-asserted-by":"crossref","unstructured":"U.S. Food and Drug Administration. Drug safety communication. FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain [article online], 2015. Available from http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm459579.htm. Accessed 8 December 2015","DOI":"10.1007\/s40278-015-5060-2"},{"key":"2022031221285805700_B22","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"2022031221285805700_B23","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"key":"2022031221285805700_B24","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"key":"2022031221285805700_B25","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.clinthera.2012.04.013","article-title":"Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review","volume":"34","author":"Aroda","year":"2012","journal-title":"Clin Ther"},{"key":"2022031221285805700_B26","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1463-1326.2011.01357.x","article-title":"An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future","volume":"13","author":"Madsbad","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"2022031221285805700_B27","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1111\/dom.12541","article-title":"Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Karagiannis","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"2022031221285805700_B28","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.2337\/dc06-2593","article-title":"Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes","volume":"30","author":"Vilsb\u00f8ll","year":"2007","journal-title":"Diabetes Care"},{"key":"2022031221285805700_B29","doi-asserted-by":"crossref","first-page":"d410","DOI":"10.1136\/bmj.d410","article-title":"Glucagon-like peptide-1 analogues for type 2 diabetes","volume":"342","author":"Wilding","year":"2011","journal-title":"BMJ"},{"key":"2022031221285805700_B30","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1185\/03007990802418851","article-title":"Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study","volume":"24","author":"DeFronzo","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"2022031221285805700_B31","doi-asserted-by":"crossref","first-page":"E846","DOI":"10.1152\/ajpendo.00030.2008","article-title":"Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes","volume":"294","author":"Cervera","year":"2008","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022031221285805700_B32","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.2337\/dc11-0291","article-title":"Effects of exenatide on measures of \u03b2-cell function after 3 years in metformin-treated patients with type 2 diabetes","volume":"34","author":"Bunck","year":"2011","journal-title":"Diabetes Care"},{"key":"2022031221285805700_B33","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(10)60307-8","article-title":"Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial","volume":"375","author":"Pratley","year":"2010","journal-title":"Lancet"},{"key":"2022031221285805700_B34","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2337\/dc08-2124","article-title":"Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD)","volume":"32","author":"Zinman","year":"2009","journal-title":"Diabetes Care"},{"key":"2022031221285805700_B35","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1210\/en.2009-1272","article-title":"Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation","volume":"151","author":"Bjerre Knudsen","year":"2010","journal-title":"Endocrinology"},{"key":"2022031221285805700_B36","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1210\/jc.2010-2318","article-title":"GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide","volume":"96","author":"Heged\u00fcs","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031221285805700_B37","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.amjmed.2010.11.004","article-title":"Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies","volume":"124","author":"Chilton","year":"2011","journal-title":"Am J Med"},{"key":"2022031221285805700_B38","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"2022031221285805700_B39","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1172\/JCI112981","article-title":"Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats","volume":"79","author":"Rossetti","year":"1987","journal-title":"J Clin Invest"},{"key":"2022031221285805700_B40","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1210\/er.2010-0029","article-title":"Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes","volume":"32","author":"Abdul-Ghani","year":"2011","journal-title":"Endocr Rev"},{"key":"2022031221285805700_B41","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol Rev"},{"key":"2022031221285805700_B42","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.3828","article-title":"Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion","volume":"21","author":"Bonner","year":"2015","journal-title":"Nat Med"},{"key":"2022031221285805700_B43","doi-asserted-by":"crossref","first-page":"F10","DOI":"10.1152\/ajprenal.2001.280.1.F10","article-title":"Renal Na(+)-glucose cotransporters","volume":"280","author":"Wright","year":"2001","journal-title":"Am J Physiol Renal Physiol"},{"key":"2022031221285805700_B44","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1463-1326.2010.01216.x","article-title":"Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight","volume":"12","author":"Zhang","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"2022031221285805700_B45","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/dom.12244","article-title":"Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials","volume":"16","author":"Monami","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"2022031221285805700_B46","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann Intern Med"},{"key":"2022031221285805700_B47","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s40264-014-0213-4","article-title":"Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events","volume":"37","author":"Ptaszynska","year":"2014","journal-title":"Drug Saf"},{"key":"2022031221285805700_B48","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1517\/14740338.2014.959488","article-title":"A safety evaluation of canagliflozin: a first-in-class treatment for type 2 diabetes","volume":"13","author":"Boyle","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"2022031221285805700_B49","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.2337\/dc13-2338","article-title":"Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial","volume":"37","author":"Perkins","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031221285805700_B50","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1007\/s00125-014-3396-4","article-title":"Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration","volume":"57","author":"Skrti\u0107","year":"2014","journal-title":"Diabetologia"},{"key":"2022031221285805700_B51","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition","volume":"38","author":"Peters","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031221285805700_B52","unstructured":"U.S. Food and Drug Administration. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections [article online], 2015. Available from http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm475463.htm. Accessed 7 December 2015"},{"key":"2022031221285805700_B53","unstructured":"European Medicines Agency. EMA confirms recommendations to minimise ketoacidosis risk with SGLT2 inhibitors for diabetes [article online], 2016. Available from http:\/\/www.ema.europa.eu:80\/ema\/index.jsp?curl=pages\/medicines\/human\/referrals\/SGLT2_inhibitors\/human_referral_prac_000052.jsp&mid=WC0b01ac05805c516f. Accessed 29 March 2016"},{"key":"2022031221285805700_B54","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2337\/diab.32.5.387","article-title":"Role of glucagon in enhancing ketone body production in ketotic diabetic man","volume":"32","author":"Keller","year":"1983","journal-title":"Diabetes"},{"key":"2022031221285805700_B55","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"key":"2022031221285805700_B56","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1210\/jc.2015-3167","article-title":"Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus","volume":"101","author":"Watts","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031221285805700_B57","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S2213-8587(14)70227-X","article-title":"Possible adverse effects of SGLT2 inhibitors on bone","volume":"3","author":"Taylor","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031221285805700_B58","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/dom.12189","article-title":"Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin","volume":"16","author":"Bolinder","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"2022031221285805700_B59","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2213-8587(13)70084-6","article-title":"Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"1","author":"Roden","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031221285805700_B60","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1007\/s00125-013-3039-1","article-title":"Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial","volume":"56","author":"Lavalle-Gonz\u00e1lez","year":"2013","journal-title":"Diabetologia"},{"key":"2022031221285805700_B61","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.2337\/dc12-2491","article-title":"Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial","volume":"36","author":"Schernthaner","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031221285805700_B62","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","article-title":"Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial","volume":"382","author":"Cefalu","year":"2013","journal-title":"Lancet"},{"key":"2022031221285805700_B63","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(14)70120-2","article-title":"Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial","volume":"2","author":"Ridderstr\u00e5le","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031221285805700_B64","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.2337\/dc11-0606","article-title":"Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial","volume":"34","author":"Nauck","year":"2011","journal-title":"Diabetes Care"},{"key":"2022031221285805700_B65","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/dom.12459","article-title":"Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data","volume":"17","author":"Del Prato","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"2022031221285805700_B66","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"2022031221285805700_B67","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1056\/NEJMoa052187","article-title":"Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes","volume":"353","author":"Nathan","year":"2005","journal-title":"N Engl J Med"},{"key":"2022031221285805700_B68","first-page":"B21","article-title":"Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients","volume":"23","author":"Shichiri","year":"2000","journal-title":"Diabetes Care"},{"key":"2022031221285805700_B69","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N Engl J Med"},{"key":"2022031221285805700_B70","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"},{"key":"2022031221285805700_B71","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N Engl J Med"},{"key":"2022031221285805700_B72","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1093\/eurheartj\/ehv239","article-title":"Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes","volume":"36","author":"Ferrannini","year":"2015","journal-title":"Eur Heart J"},{"key":"2022031221285805700_B73","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/dmrr.1092","article-title":"The A1C and ABCD of glycaemia management in type 2 diabetes: a physician\u2019s personalized approach","volume":"26","author":"Pozzilli","year":"2010","journal-title":"Diabetes Metab Res Rev"},{"key":"2022031221285805700_B74","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"key":"2022031221285805700_B75"},{"key":"2022031221285805700_B76","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/dom.12417","article-title":"Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial","volume":"17","author":"Abdul-Ghani","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"2022031221285805700_B77","first-page":"168","article-title":"Insulin vs GLP-1 analogues in poorly controlled type 2 diabetic subjects on oral therapy: a meta-analysis","volume":"36","author":"Abdul-Ghani","year":"2013","journal-title":"J Endocrinol Invest"},{"key":"2022031221285805700_B78","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1185\/030079908X253870","article-title":"Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years","volume":"24","author":"Klonoff","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"2022031221285805700_B79","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.2337\/dc13-2759","article-title":"Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3)","volume":"37","author":"Umpierrez","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031221285805700_B80","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1016\/S0140-6736(12)60479-6","article-title":"Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial","volume":"379","author":"Gallwitz","year":"2012","journal-title":"Lancet"},{"key":"2022031221285805700_B81","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2337\/dc09-1749","article-title":"Secondary failure of metformin monotherapy in clinical practice","volume":"33","author":"Brown","year":"2010","journal-title":"Diabetes Care"},{"key":"2022031221285805700_B82","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N Engl J Med"},{"key":"2022031221285805700_B83","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2337\/dc08-1355","article-title":"Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)-2 study","volume":"32","author":"Nauck","year":"2009","journal-title":"Diabetes Care"},{"key":"2022031221285805700_B84","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1463-1326.2010.01356.x","article-title":"Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes","volume":"13","author":"Garber","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"2022031221285805700_B85"},{"key":"2022031221285805700_B86","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1463-1326.2008.00994.x","article-title":"Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy","volume":"11","author":"Ferrannini","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"2022031221285805700_B87","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.2337\/dc14-0024","article-title":"HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin","volume":"37","author":"Ahr\u00e9n","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031221285805700_B88","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"38","author":"Inzucchi","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031221285805700_B89","doi-asserted-by":"crossref","first-page":"103","DOI":"10.7326\/0003-4819-154-2-201101180-00300","article-title":"Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial","volume":"154","author":"Buse","year":"2011","journal-title":"Ann Intern Med"},{"key":"2022031221285805700_B90","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1016\/S0140-6736(14)61335-0","article-title":"Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis","volume":"384","author":"Eng","year":"2014","journal-title":"Lancet"},{"key":"2022031221285805700_B91","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.2337\/dc14-0876","article-title":"Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes","volume":"37","author":"Diamant","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031221285805700_B92","doi-asserted-by":"crossref","first-page":"405","DOI":"10.7326\/0003-4819-156-6-201203200-00003","article-title":"Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial","volume":"156","author":"Wilding","year":"2012","journal-title":"Ann Intern Med"},{"key":"2022031221285805700_B93"},{"key":"2022031221285805700_B94","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","article-title":"Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial","volume":"373","author":"Home","year":"2009","journal-title":"Lancet"},{"key":"2022031221285805700_B95","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2022031221285805700_B96","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2337\/diab.37.6.667","article-title":"Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM","volume":"37","author":"DeFronzo","year":"1988","journal-title":"Diabetes"},{"key":"2022031221285805700_B97","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus","volume":"58","author":"Defronzo","year":"2009","journal-title":"Diabetes"},{"key":"2022031221285805700_B98","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2337\/dc14-2364","article-title":"Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin","volume":"38","author":"DeFronzo","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031221285805700_B99","doi-asserted-by":"crossref","first-page":"376","DOI":"10.2337\/dc14-1142","article-title":"Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031221285805700_B100","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest"},{"key":"2022031221285805700_B101","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"J Clin Invest"},{"key":"2022031221285805700_B102","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2337\/dc10-0612","article-title":"Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"33","author":"Ferrannini","year":"2010","journal-title":"Diabetes Care"},{"key":"2022031221285805700_B103","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/MNH.0000000000000084","article-title":"Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy","volume":"24","author":"\u0160krti\u0107","year":"2015","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2022031221285805700_B104","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"2022031221285805700_B105","doi-asserted-by":"crossref","first-page":"e54442","DOI":"10.1371\/journal.pone.0054442","article-title":"Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy","volume":"8","author":"Panchapakesan","year":"2013","journal-title":"PLoS One"},{"key":"2022031221285805700_B106","doi-asserted-by":"crossref","first-page":"3","DOI":"10.14814\/phy2.12436","article-title":"Renoprotective effects of combined SGLT2 and ACE inhibitor therapy in diabetic Dahl S rats","volume":"3","author":"Kojima","year":"2015","journal-title":"Physiol Rep"},{"key":"2022031221285805700_B107"},{"key":"2022031221285805700_B108","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1007\/s00125-015-3653-1","article-title":"Sequential induction of beta cell rest and stimulation using stable GIP inhibitor and GLP-1 mimetic peptides improves metabolic control in C57BL\/KsJ db\/db mice","volume":"58","author":"Pathak","year":"2015","journal-title":"Diabetologia"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/39\/Supplement_2\/S154\/548815\/dcs153005.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/39\/Supplement_2\/S154\/548815\/dcs153005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T13:08:18Z","timestamp":1656853698000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/39\/Supplement_2\/S154\/30367\/Positioning-SGLT2-Inhibitors-Incretin-Based"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,16]]},"references-count":108,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2016,7,16]]},"published-print":{"date-parts":[[2016,8,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dcs15-3005","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,16]]}}}